Literature DB >> 16432029

Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture.

David Marchant1, Stuart J D Neil1, Áine McKnight1.   

Abstract

This study compares the replication of primary isolates of human immunodeficiency virus type 2 (HIV-2) and type 1 (HIV-1) in monocyte-derived macrophages (MDMs). Eleven HIV-2 and five HIV-1 primary isolates that use CCR5, CXCR4 or both coreceptors to enter cells were included. Regardless of coreceptor preference, 10 of 11 HIV-2 viruses could enter, reverse transcribe and produce fully infectious virus in MDMs with efficiency equal to that in peripheral blood mononuclear cells. However, the kinetics of replication of HIV-2 compared with HIV-1 over time were distinct. HIV-2 had a burst of virus replication 2 days after infection that resolved into an apparent 'latent state' at day 3. HIV-1, however, continued to produce infectious virions at a lower, but steady, rate throughout the course of infection. These results may have implications for the lower pathogenesis and viral-load characteristics of HIV-2 infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432029     DOI: 10.1099/vir.0.81391-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  17 in total

1.  Metabolic profiling during HIV-1 and HIV-2 infection of primary human monocyte-derived macrophages.

Authors:  Joseph A Hollenbaugh; Catherine Montero; Raymond F Schinazi; Joshua Munger; Baek Kim
Journal:  Virology       Date:  2016-02-16       Impact factor: 3.616

2.  Anti-HIV host factor SAMHD1 regulates viral sensitivity to nucleoside reverse transcriptase inhibitors via modulation of cellular deoxyribonucleoside triphosphate (dNTP) levels.

Authors:  Sarah M Amie; Michele B Daly; Erin Noble; Raymond F Schinazi; Robert A Bambara; Baek Kim
Journal:  J Biol Chem       Date:  2013-06-05       Impact factor: 5.157

3.  In vivo emergence of HIV-1 highly sensitive to neutralizing antibodies.

Authors:  Marlén M I Aasa-Chapman; Kelly M Cheney; Stéphane Hué; Anna Forsman; Stephen O'Farrell; Pierre Pellegrino; Ian Williams; Áine McKnight
Journal:  PLoS One       Date:  2011-08-24       Impact factor: 3.240

4.  Interferon-alpha mediates restriction of human immunodeficiency virus type-1 replication in primary human macrophages at an early stage of replication.

Authors:  Kelly M Cheney; Áine McKnight
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

5.  Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection.

Authors:  Melody G Duvall; Karin Loré; Hetty Blaak; David A Ambrozak; William C Adams; Kathlyn Santos; Christof Geldmacher; John R Mascola; Andrew J McMichael; Assan Jaye; Hilton C Whittle; Sarah L Rowland-Jones; Richard A Koup
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

Review 6.  Engineering broadly neutralizing antibodies for HIV prevention and therapy.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Adv Drug Deliv Rev       Date:  2016-01-29       Impact factor: 15.470

7.  Inhibitory Effects of HIV-2 Vpx on Replication of HIV-1.

Authors:  Mohamed Mahdi; Zsófia Szojka; János András Mótyán; József Tőzsér
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

8.  A novel envelope mediated post entry restriction of murine leukaemia virus in human cells is Ref1/TRIM5α independent.

Authors:  Nidia M M Oliveira; Roochi Trikha; Áine McKnight
Journal:  Retrovirology       Date:  2010-10-07       Impact factor: 4.602

9.  A whole genome screen for HIV restriction factors.

Authors:  Li Liu; Nidia M M Oliveira; Kelly M Cheney; Corinna Pade; Hanna Dreja; Ann-Marie H Bergin; Viola Borgdorff; David H Beach; Cleo L Bishop; Matthias T Dittmar; Aine McKnight
Journal:  Retrovirology       Date:  2011-11-14       Impact factor: 4.602

10.  Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages.

Authors:  Li Zhao; Shumei Wang; Meng Xu; Yang He; Xiaowei Zhang; Ying Xiong; Hong Sun; Haibo Ding; Wenqing Geng; Hong Shang; Guoxin Liang
Journal:  Nat Commun       Date:  2021-06-17       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.